Rights and permissions
About this article
Cite this article
Prolonging antiandrogen therapy appears to improve survival duration in patients with stage D2 prostate cancer. Inpharma Wkly. 1233, 11 (2000). https://doi.org/10.2165/00128413-200012330-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200012330-00020